W.M. Keck Foundation to support research on healthy aging at MIT

Assistant Professor of Biology Alison Ringel will investigate the intersection of immunology and aging biology, aiming to define the mechanisms that underlie aging-related decline, thanks to grant from prestigious foundation.

Lillian Eden | Department of Biology
October 9, 2025

A prestigious grant from the W.M. Keck Foundation to Assistant Professor of Biology Alison Ringel will support groundbreaking healthy aging research at MIT.

Ringel, also a Core Member of the Ragon Institute, will draw on her background in cancer immunology to create a more comprehensive biomedical understanding of the cause and possible treatments for aging-related decline.

“It is such an honor to receive this grant,” Ringel says. “This support will enable us to draw new connections between immunology and aging biology. As the U.S. population grows older, advancing this research is increasingly important, and this line of inquiry is only possible because of the W.M. Keck Foundation.”

Understanding how to extend healthy years of life is a fundamental question of biomedical research with wide-ranging societal implications. Although modern science and medicine have greatly expanded global life expectancy, it remains unclear why everyone ages differently; some maintain physical and cognitive fitness well into old age, while others become debilitatingly frail later in life.

Our immune systems are adaptable, but they do naturally decline as we get older. One critical component of our immune system is CD8+ T cells, which are known to target and destroy cancerous or damaged cells. As we age, our tissues accumulate cells that can no longer divide. These senescent cells are present throughout our lives, but reach seemingly harmful levels as a normal part of aging, causing tissue damage and diminished resilience under stress.

There is now compelling evidence that the immune system plays a more active role in aging than previously thought.

“Decades of research have revealed that T cells can eliminate cancer cells, and studies of how they do so have led directly to the development of cancer immunotherapy,” Ringel says. “Building on these discoveries, we can now ask what roles T cells play in normal aging, where the accumulation of senescent cells, which are remarkably similar to cancer cells in some respects, may cause health problems later in life.”

In animal models, reconstituting elements of a young immune system has been shown to improve age-related decline, potentially due to CD8+ T cells selectively eliminating senescent cells. CD8+ T cells progressively losing the ability to cull senescent cells could explain some age-related pathology.

Ringel aims to build models for the express purpose of tracking and manipulating T cells in the context of aging and to evaluate how T cell behavior changes over a lifespan.

“By defining the protective processes that slow aging when we are young and healthy, and defining how these go awry in older adults, our goal is to generate knowledge that can be applied to extend healthy years of life,” Ringel says. “I’m really excited about where this research can take us.”

The W. M. Keck Foundation was established in 1954 in Los Angeles by William Myron Keck, founder of The Superior Oil Company. One of the nation’s largest philanthropic organizations, the W. M. Keck Foundation supports outstanding science, engineering and medical research. The Foundation also supports undergraduate education and maintains a program within Southern California to support arts and culture, education, health and community service projects.

Rudolf Jaenisch awarded Ogawa-Yamanaka Stem Cell Prize

Rudolf Jaenisch is recognized for his trailblazing contributions to epigenetics and stem cell biology, which have shaped modern regenerative medicine.

Sarah Stanley | Gladstone Institutes
August 28, 2025

Rudolf Jaenisch, MD, was announced today as the recipient of the 2025 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes. He was selected for his trailblazing contributions to epigenetics and stem cell biology. His pivotal discoveries have profoundly advanced our understanding of gene regulation, cellular reprogramming, and the potential of regenerative medicine.

A founding member of the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, Jaenisch is also a professor of biology at the Massachusetts Institute of Technology. He is widely recognized for his role in establishing the use in science of induced pluripotent stem (iPS) cells—adult cells that have been reprogrammed into an embryonic stem cell–like state with the potential to become any cell type in the body.

Among his many achievements, Jaenisch was the first to show the potential therapeutic applications of iPS cells after they were discovered by Gladstone Senior Investigator Shinya Yamanaka, MD, PhD. In fact, Jaenisch effectively cured mice of sickle cell anemia by using iPS cells that had been derived from the animals’ own skin cells and in which the disease-causing genetic defect had been corrected.

“Until then, iPS cells were just an exciting lab tool—but Dr. Jaenisch provided the first real proof that they could be used to treat human disease,” says Deepak Srivastava, MD, chair of the selection committee, president of Gladstone Institutes, and director of the Rodenberry Stem Cell Center at Gladstone. “We’re very happy to recognize his outstanding career with this year’s award. His many contributions to stem cell research and disease modeling have helped shape modern regenerative medicine as we know it.”

Jaenisch has been at the forefront of exploring, expanding, and refining the processes by which iPS cells are created and applied in labs around the world. His work has opened the door to the development of therapies for a wide range of genetic and degenerative diseases.

Since its establishment in 2015, the Ogawa-Yamanaka Stem Cell Prize has honored scientists and doctors leading groundbreaking work in translational regenerative medicine using reprogrammed cells. Each year, it is made possible by a generous gift from the Hiro and Betty Ogawa family.

The prize, supported by Gladstone and Cell Press, also pays tribute to Yamanaka, whose discovery of iPS cells earned him a Nobel Prize in 2012 and is tightly intertwined with Jaenisch’s work.

“Shinya’s discovery completely transformed the world of stem cell science and opened up so many promising new paths for understanding and addressing disease,” Jaenisch says. “What an honor it is to be recognized for my contributions in this field.”

One of Jaenisch’s earliest marks on science came in 1974, when he co-created the first transgenic animal—an organism whose genetic material has been intentionally altered by adding foreign genes—with pioneering embryologist Beatrice Mintz, PhD. This work became the foundation for genetically engineered animal models, which are used in nearly every area of biomedical research today.

“This single study was a major leap in molecular biology,” says Srivastava. “It gave birth to the very concept of modeling human diseases in animals, allowing scientists to deliberately change an animal’s genetic code in order to study the mechanisms of disease and test therapies.”

In his more than 40 years at the Whitehead Institute, Jaenisch has led research exploring how stem cells and reprogramming technologies could be harnessed to better understand and treat disease. In the process, he has continued to develop innovative tools, including adapting CRISPR technology for gene editing and epigenome editing in stem cell systems.

An independent committee of international stem cell experts selected Jaenisch for the 2025 Ogawa-Yamanaka Stem Cell Prize from a highly competitive pool of nominees. As this year’s winner, he will receive an unrestricted prize of $150,000. Gladstone will host a ceremony on December 1, 2025, in San Francisco, California, where Jaenisch will deliver a scientific lecture and be presented with the award.

About Gladstone Institutes

Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.

About Rudolf Jaenisch

Rudolf Jaenisch, MD, is a founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered.

Jaenisch received his MD from the University of Munich in 1967 and carried out postdoctoral research at Princeton University, Fox Chase Institute for Cancer Research, and the Salk Institute. Before joining Whitehead in 1982, he was head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg.

His current research focuses on the epigenetic regulation of gene expression, which has led to major advances in creating embryonic stem cells and iPS cells, as well as their therapeutic applications. His lab also focuses on the epigenetic mechanisms involved in cancer and brain development, as well as coronavirus biology.

Jaenisch has co-authored more than 500 research papers and received various awards during his career, including the Max Delbrück Medal, the Vilcek Prize, the National Medal of Science, the Wolf Prize in Medicine, and the Otto Warburg Medal. He is a fellow of the American Academy of Arts and Sciences and an elected member of the U.S. National Academy of Sciences. He also was president of the International Society for Stem Cell Research in 2014–15.

About the Ogawa-Yamanaka Stem Cell Prize

The Ogawa-Yamanaka Stem Cell Prize recognizes individuals whose original translational research has advanced cellular reprogramming technology for regenerative medicine. Supported by Gladstone Institutes, in partnership with Cell Press, the prize was established in 2015 through a generous gift from Betty and Hiro Ogawa. It has been maintained through their sons, Andrew and Marcus Ogawa, to honor the Ogawas’ memory by continuing the philanthropic legacy they shared during their 46-year marriage. It also recognizes the importance of induced pluripotent stem cells (iPS cells), discovered by Gladstone Senior Investigator and Nobel laureate Shinya Yamanaka, MD, PhD.

Past recipients include Masayo Takahashi, MD, PhD, in 2015; Douglas Melton, PhD, in 2016; Lorenz Studer, MD, in 2017; Marius Wernig, MD, PhD, in 2018; Gordon Keller, PhD, in 2019; Juan Carlos Izpisua Belmonte, PhD, in 2022; Magdalena Zernicka-Goetz, PhD, in 2023; and Rusty Gage, PhD, in 2025.

The 2025 selection committee was composed of George Daley, MD, PhD, dean of Harvard Medical School; Hideyuki Okano, MD, PhD, dean of the School of Medicine at Keio University; Deepak Srivastava, MD, president of Gladstone Institutes and director of the Roddenberry Stem Cell Center at Gladstone; Lorenz Studer, MD, director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center; Fiona Watt, FRS, FMedSci, director of the Centre for Stem Cells and Regenerative Medicine at King’s College, London; and Shinya Yamanaka, MD, PhD, senior investigator at Gladstone and director emeritus of the Center for iPS Cell Research and Application at Kyoto University.

2025 Amon Award Winners Announced

Congratulations to the winners of the 2025 Angelika Amon Young Scientist Award: Sourav Ghosh of the Indian Institute of Technology Bombay, and Kotaro Tomuro of RIKEN and The University of Tokyo.

Koch Institute
August 12, 2025

Established in 2021, the Angelika Amon Young Scientist Award recognizes graduate students in the life sciences or biomedical research from institutions outside the United States who embody Dr. Amon’s infectious enthusiasm for discovery science.

Sourav Ghosh, a PhD student in Biotechnology at the Indian Institute of Technology Bombay under the supervision of Anirban Banerjee, investigates cell-autonomous immunity—the ability of host cells to defend themselves against intracellular pathogens. His work uncovered a unique bacteriolytic role for VCP/p97, a host AAA-ATPase or enzyme that uses mechanical force to extract ubiquitinated proteins from bacterial surfaces, rupturing the pathogens and releasing their contents. This process protects the host from lethal sepsis and reveals VCP/p97 as a broad-spectrum defense effector. Ghosh’s findings, published in Nature Microbiology, open new avenues for therapeutic interventions against bacterial infections.

Kotaro Tomuro, a PhD candidate at the RIKEN Pioneering Research Institute and the Graduate School of Frontier Sciences at The University of Tokyo, works under the supervision of Shintaro Iwasaki. Tomuro develops cutting-edge ribosome profiling methods to investigate the spatial and temporal regulation of translation—the process by which genetic information is converted into proteins. His innovations include “Ribo-Calibration,” an approach that enables absolute quantification of translation rates, and “APEX-Ribo-Seq,” which profiles protein synthesis within specific cellular compartments. Together, these tools have generated a detailed atlas of where and when proteins are made in the cell, revealing new principles of gene expression with potential applications in neurobiology, cancer research, and RNA-based therapeutics.

Ghosh and Tomuro will present their research at the Amon Award ceremony on Thursday, November 6, at 10 a.m. in the Luria Auditorium, followed by an 11:30 a.m. reception in the Koch Institute Public Galleries.

The MIT community and Amon Lab alumni are invited to attend.

Sebastian Lourido awarded highest alumni honor from alma mater

Whitehead Institute Member Sebastian Lourido receives the Tulane 2025 Science and Engineering Outstanding Alumni Award for Professional Excellence

Whitehead Institute
April 11, 2025

The Lourido laboratory at Whitehead Institute studies the developmental transitions and molecular pathways that the single cell parasite Toxoplasma gondii (T. gondii ), uses to infect its host, causing toxoplasmosis.They combine several approaches that span phospho-proteomics, chemical-genetics, and genome editing to investigate the unique biology of these organisms and identify specific features that can be targeted to treat infections of T. gondii and related parasites.

Lourido, who is also an associate professor of biology at Massachusetts Institute of Technology, originally joined Whitehead Institute as a Whitehead Fellow in 2012, a program that allows promising MD or PhD graduates to initiate their own research program in lieu of a traditional postdoctoral fellowship. “Sebastian’s demonstrated excellence as a young investigator underscores the importance of investing in the next generation of scientists and scientific leaders,” says Ruth Lehmann, Whitehead Institute’s President and Director.

After receiving both a BS in Cell and Molecular Biology and a BFA in Studio Art, Lourido went on to pursue graduate work at Washington University in St. Louis. In addition to this honor, Lourido has also been the recipient of other awards including the NIH Director’s Early Independence Award and the 2024 William Trager Award from the American Society of Tropical Medicine and Hygiene and was recognized as one of the Burroughs Wellcome Fund’s Investigators in the Pathogenesis of Infectious Disease.

Whitehead Institute Member Sebastian Lourido receives the 2024 William Trager Award

Sebastian Lourido was awarded the 2024 William Trager Award by the American Society of Tropical Medicine and Hygiene for his pioneering use of CRISPR tools to study the biology of Toxoplasma gondii, a single-celled parasite that infects about 25% of humans.

Merrill Meadow | Whitehead Institute
November 14, 2024

The Trager Award recognizes scientists who have made substantial contributions to the study of basic parasitology through breakthroughs that have unlocked completely new areas of work.

ASTMH selected Lourido — who is also an associate professor of Biology at Massachusetts Institute of Technology and holds the Landon Clay Career Development Chair at Whitehead Institute — in recognition of his groundbreaking discoveries on the molecular biology of Toxoplasma. In particular, Lourido has been lauded for his use of cutting-edge CRISPR tools to study the fundamental biology of Toxoplasma gondii, a single-celled parasite that infects about 25 percent of humans.

“My laboratory colleagues and I are grateful for this recognition of our work, and for the wonderful opportunity it presents to more widely share the ideas and tools we have developed,” says Lourido, who will deliver a talk on his research at the ASTMH Annual Meeting in New Orleans on Nov. 15, 2024.

Matthew Vander Heiden among those elected to National Academy of Medicine for 2024

Professor Matthew Vander Heiden and Biology alum Konstantina M. Stankovic are honored for their outstanding professional achievement and commitment to service.

Nina Tamburello | Koch Institute
October 22, 2024

The National Academy of Medicine recently announced the election of more than 90 members during its annual meeting, including MIT faculty members Matthew Vander Heiden and Fan Wang, along with five MIT alumni.

Election to the National Academy of Medicine (NAM) is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

Matthew Vander Heiden is the director of the Koch Institute for Integrative Cancer Research at MIT, a Lester Wolfe Professor of Molecular Biology, and a member of the Broad Institute of MIT and Harvard. His research explores how cancer cells reprogram their metabolism to fuel tumor growth and has provided key insights into metabolic pathways that support cancer progression, with implications for developing new therapeutic strategies. The National Academy of Medicine recognized Vander Heiden for his contributions to “the development of approved therapies for cancer and anemia” and his role as a “thought leader in understanding metabolic phenotypes and their relations to disease pathogenesis.”

Vander Heiden earned his MD and PhD from the University of Chicago and completed  his clinical training in internal medicine and medical oncology at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. After postdoctoral research at Harvard Medical School, Vander Heiden joined the faculty of the MIT Department of Biology and the Koch Institute in 2010. He is also a practicing oncologist and instructor in medicine at Dana-Farber Cancer Institute and Harvard Medical School.

Fan Wang is a professor of brain and cognitive sciences, an investigator at the McGovern Institute, and director of the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics at MIT.  Wang’s research focuses on the neural circuits governing the bidirectional interactions between the brain and body. She is specifically interested in the circuits that control the sensory and emotional aspects of pain and addiction, as well as the sensory and motor circuits that work together to execute behaviors such as eating, drinking, and moving. The National Academy of Medicine has recognized her body of work for “providing the foundational knowledge to develop new therapies to treat chronic pain and movement disorders.”

Before coming to MIT in 2021, Wang obtained her PhD from Columbia University and received her postdoctoral training at the University of California at San Francisco and Stanford University. She became a faculty member at Duke University in 2003 and was later appointed the Morris N. Broad Professor of Neurobiology. Wang is also a member of the American Academy of Arts and Sciences and she continues to make important contributions to the neural mechanisms underlying general anesthesia, pain perception, and movement control.

MIT alumni who were elected to the NAM for 2024 include:

  • Leemore Dafny PhD ’01 (Economics);
  • David Huang ’85 MS ’89  (Electrical Engineering and Computer Science) PhD ’93 Medical Engineering and Medical Physics);
  • Nola M. Hylton ’79 (Chemical Engineering);
  • Mark R. Prausnitz PhD ’94 (Chemical Engineering); and
  • Konstantina M. Stankovic ’92 (Biology and Physics) PhD ’98 (Speech and Hearing Bioscience and Technology)

Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the National Academy of Medicine addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors.

“This class of new members represents the most exceptional researchers and leaders in health and medicine, who have made significant breakthroughs, led the response to major public health challenges, and advanced health equity,” said National Academy of Medicine President Victor J. Dzau. “Their expertise will be necessary to supporting NAM’s work to address the pressing health and scientific challenges we face today.”

Victor Ambros ’75, PhD ’79 and Gary Ruvkun share Nobel Prize in Physiology or Medicine

The scientists, who worked together as postdocs at MIT, are honored for their discovery of microRNA — a class of molecules that are critical for gene regulation.

Anne Trafton | MIT News
October 7, 2024

MIT alumnus Victor Ambros ’75, PhD ’79 and Gary Ruvkun, who did his postdoctoral training at MIT, will share the 2024 Nobel Prize in Physiology or Medicine, the Royal Swedish Academy of Sciences announced this morning in Stockholm.

Ambros, a professor at the University of Massachusetts Chan Medical School, and Ruvkun, a professor at Harvard Medical School and Massachusetts General Hospital, were honored for their discovery of microRNA, a class of tiny RNA molecules that play a critical role in gene control.

“Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function,” the Nobel committee said in its announcement today.

During the late 1980s, Ambros and Ruvkun both worked as postdocs in the laboratory of H. Robert Horvitz, a David H. Koch Professor at MIT, who was awarded the Nobel Prize in 2002.

While in Horvitz’s lab, the pair began studying gene control in the roundworm C. elegans — an effort that laid the groundwork for their Nobel discoveries. They studied two mutant forms of the worm, known as lin-4 and lin-14, that showed defects in the timing of the activation of genetic programs that control development.

In the early 1990s, while Ambros was a faculty member at Harvard University, he made a surprising discovery. The lin-4 gene, instead of encoding a protein, produced a very short RNA molecule that appeared in inhibit the expression of lin-14.

At the same time, Ruvkun was continuing to study these C. elegans genes in his lab at MGH and Harvard. He showed that lin-4 did not inhibit lin-14 by preventing the lin-14 gene from being transcribed into messenger RNA; instead, it appeared to turn off the gene’s expression later on, by preventing production of the protein encoded by lin-14.

The two compared results and realized that the sequence of lin-4 was complementary to some short sequences of lin-14. Lin-4, they showed, was binding to messenger RNA encoding lin-14 and blocking it from being translated into protein — a mechanism for gene control that had never been seen before. Those results were published in two articles in the journal Cell in 1993.

In an interview with the Journal of Cell Biology, Ambros credited the contributions of his collaborators, including his wife, Rosalind “Candy” Lee ’76, and postdoc Rhonda Feinbaum, who both worked in his lab, cloned and characterized the lin-4 microRNA, and were co-authors on one of the 1993 Cell papers.

In 2000, Ruvkun published the discovery of another microRNA molecule, encoded by a gene called let-7, which is found throughout the animal kingdom. Since then, more than 1,000 microRNA genes have been found in humans.

“Ambros and Ruvkun’s seminal discovery in the small worm C. elegans was unexpected, and revealed a new dimension to gene regulation, essential for all complex life forms,” the Nobel citation declared.

Ambros, who was born in New Hampshire and grew up in Vermont, earned his PhD at MIT under the supervision of David Baltimore, then an MIT professor of biology, who received a Nobel Prize in 1973. Ambros was a longtime faculty member at Dartmouth College before joining the faculty at the University of Massachusetts Chan Medical School in 2008.

Ruvkun is a graduate of the University of California at Berkeley and earned his PhD at Harvard University before joining Horvitz’s lab at MIT.

2024 Angelika Amon Young Scientist award winners announced

The Koch Institute at MIT is pleased to announce the winners of the 2024 Angelika Amon Young Scientist Award, Anna Uzonyi and Lukas Teoman Henneberg.

Koch Institute
September 3, 2024

The Koch Institute at MIT is pleased to announce the winners of the 2024 Angelika Amon Young Scientist Award, Anna Uzonyi and Lukas Teoman Henneberg.

The prize was established in 2021 to recognize graduate students in the life sciences or biomedical research from institutions outside the United States who embody Dr. Amon’s infectious enthusiasm for discovery science.

Both of this year’s winners work to unravel the fundamental biology of chromatin, the densely structured complex of DNA, RNA, and proteins that makes up a cell’s genetic material.

Uzonyi is pursuing her PhD at the Weizmann Institute of Science in Israel under the supervision of Schraga Schwartz and Yonatan Stelzer. In her thesis, Uzonyi focuses on deciphering the principles of RNA editing code via large-scale systematic probing.

Henneberg is a doctoral candidate in the Department of Molecular Machines and Signaling, at the Max Planck Institute of Biochemistry in Germany, works under the supervision of Professor Brenda Schulman and Professor Matthias Mann. For his research project, he probes active ubiquitin E3 ligase networks within cells. He works on the development of probes targeting active ubiquitin E3 ligases within cells and utilizing them in mass spectrometry-based workflows to explore the response of these ligase networks to cellular signaling pathways and therapeutics.

This fall, Anna Uzonyi and Lukas Teoman Henneberg, will visit the Koch Institute. The MIT community and Amon Lab alumni are invited to attend their scientific presentations on Thursday, November 14 at 2:00 p.m. in the Luria Auditorium, followed by a 3:30 p.m. reception in the KI Galleries.

Uzonyi will present on “Inosine and m6A: Deciphering the deposition and function of adenosine modifications” and Henneberg will present on “Capturing active cellular destroyers: Probing dynamic ubiquitin E3 ligase networks.

Two Whitehead Institute graduate researchers awarded the 2024 Regeneron Prize for Creative Innovation

Whitehead Institute graduate student researchers Christopher Giuliano (Lourido Lab) and Julian Roessler (Hrvatin Lab) have been awarded the 2024 Regeneron Prize for Creative Innovation.

Merrill Meadow | Whitehead Institute
July 30, 2024

Whitehead Institute graduate student researchers Christopher Giuliano and Julian Roessler have been awarded the 2024 Regeneron Prize for Creative Innovation. In addition, postdoctoral researcher Chen Weng was selected as a finalist in the postdoctoral fellows competition.

The Regeneron Prize, sponsored by global biotechnology company Regeneron Pharmaceuticals, Inc., is a competitive award designed to recognize and honor exceptional talent and originality in biomedical research. Individual graduate students and postdoctoral fellows in the biomedical sciences are nominated by the nation’s top research universities. Then, nominees outline their “Dream Projects” — potentially groundbreaking research projects that they would pursue given unrestricted access to resources and state-of-the-art technology.

The “Dream Project” proposals, presented by the nominees to a selection committee comprised of Regeneron’s leading scientists, are used to evaluate a trainee’s scientific merit, elegance, precision, and creativity. Novel research ideas and out-of-the-box thinking is encouraged — although the proposal must include a strong rationale, basic methodology and design for the project, and a discussion of how its results could advance the field. Both Giuliano and Roessler have been awarded $50,000 for their proposals, which can be used in any way the winners choose. In addition, Weng was awarded $5,000 as a finalist, and Regeneron has made a $10,000 grant to the Whitehead Institute as the home institute of the winners to support its seminar series.

This year’s awards are distinctive in that the two winners are from the same institution: Both Giuliano and Roessler are pursuing their PhDs at Massachusetts Institute of Technology (MIT) and conducting their doctoral research at Whitehead Institute.

Giuliano is a researcher in the lab of Whitehead Institute Member Sebastian Lourido, who is also an associate professor of biology at MIT and holds the Landon Clay Career Development Chair at Whitehead Institute. Giuliano’s Dream Project seeks to address the unique challenges posed by genetically based muscle disorders. “An obstacle in using current gene therapies to treat these conditions,” he explains, “is that muscle tissue comprises large syncytial cells, which contain hundreds of nuclei in a shared cytoplasm. Even when a gene therapy is able to reach an individual muscle cell, it often isn’t able to spread to every nucleus within that cell.” However, certain parasites, like Toxoplasma gondii, thrive because they have the capacity to successfully gain access to and manipulate muscle cells. T. gondii, the primary focus of the Lourido lab’s work, may infect nearly one third of all humans. “My project,” Giuliano says, “would identify the specific biological mechanisms used by the parasites to spread their virulence factor proteins throughout the cell. Using genetic screens for protein spread, we would work toward applying these protein features to improve the efficiency of muscle-directed gene therapies, and ultimately test our system in a mouse model of Duchenne muscular dystrophy.”

Roessler is a researcher in the lab of Whitehead Institute Member Siniša Hrvatin, who is also an assistant professor of biology at MIT. While Roessler’s doctoral research focuses on the neuronal circuitry underlying torpor and hibernation in small mammals, his Dream Project seeks to identify the sensory circuitry regulating the “diving reflex” displayed in land- and sea-dwelling mammals, including humans. The diving reflex occurs when an animal’s face is immersed in cold water, prompting an array of organs to reduce their function in ways that, scientists believe, privileges the flow of oxygen to the brain and muscles. “That this reflex has been conserved across millions of years of mammalian evolution suggests an extraordinary genetic advantage,” Roessler says. “Yet, researchers have given comparatively little attention to the neuronal circuits underlying this reflex, and we don’t understand even the fundamental mechanisms by which the nervous system coincidently detects both cold temperature and the presence of water.” Beyond elucidating a foundational aspect of mammalian biology, Roessler’s projects could, if pursued, underpin new interventions for conditions ranging from migraine headaches to cardiac arrhythmia that might be ameliorated by artificial stimulation or inhibition of the diving response.

Weng is a postdoctoral researcher in the lab of Whitehead Institute Member Jonathan Weissman, who is also a professor of biology at MIT, the Landon T. Clay Professor of Biology at Whitehead Institute, and an Investigator of the Howard Hughes Medical Institute. His Dream Project — which proposes a new approach to using single-cell genealogy to understand factors driving cell line evolution — is an extension of his current work. Indeed, this past year he co-developed a technology that details the family trees of human blood cells and provides new insights into the differences between lineages of hematopoietic stem cells. The technology gives researchers unprecedented access to any human cells’ histories — and a path to resolving previously unanswerable questions.

MIT affiliates named 2024 HHMI Investigators

Four faculty members and four others with MIT ties are recognized for pushing the boundaries of science and for creating highly inclusive and collaborative research environments.

School of Science
July 23, 2024

The Howard Hughes Medical Institute (HHMI) today announced its 2024 investigators, four of whom hail from the School of Science at MIT: Steven Flavell, Mary Gehring, Mehrad Jazayeri, and Gene-Wei Li.

Four others with MIT ties were also honored: Jonathan Abraham, graduate of the Harvard/MIT MD-PhD Program; Dmitriy Aronov PhD ’10; Vijay Sankaran, graduate of the Harvard/MIT MD-PhD Program; and Steven McCarroll, institute member of the Broad Institute of MIT and Harvard.

Every three years, HHMI selects roughly two dozen new investigators who have significantly impacted their chosen disciplines to receive a substantial and completely discretionary grant. This funding can be reviewed and renewed indefinitely. The award, which totals roughly $11 million per investigator over the next seven years, enables scientists to continue working at their current institution, paying their full salary while providing financial support for researchers to be flexible enough to go wherever their scientific inquiries take them.

Of the almost 1,000 applicants this year, 26 investigators were selected for their ability to push the boundaries of science and for their efforts to create highly inclusive and collaborative research environments.

“When scientists create environments in which others can thrive, we all benefit,” says HHMI president Erin O’Shea. “These newest HHMI Investigators are extraordinary, not only because of their outstanding research endeavors but also because they mentor and empower the next generation of scientists to work alongside them at the cutting edge.”

Steven Flavell

Steven Flavell, associate professor of brain and cognitive sciences and investigator in the Picower Institute for Learning and Memory, seeks to uncover the neural mechanisms that generate the internal states of the brain, for example, different motivational and arousal states. Working in the model organism, the C. elegans worm, the lab has used genetic, systems, and computational approaches to relate neural activity across the brain to precise features of the animal’s behavior. In addition, they have mapped out the anatomical and functional organization of the serotonin system, mapping out how it modulates the internal state of C. elegans. As a newly named HHMI Investigator, Flavell will pursue research that he hopes will build a foundational understanding of how internal states arise and influence behavior in nervous systems in general. The work will employ brain-wide neural recordings, computational modeling, expansive research on neuromodulatory system organization, and studies of how the synaptic wiring of the nervous system constrains an animal’s ability to generate different internal states.

“I think that it should be possible to define the basis of internal states in C. elegans in concrete terms,” Flavell says. “If we can build a thread of understanding from the molecular architecture of neuromodulatory systems, to changes in brain-wide activity, to state-dependent changes in behavior, then I think we’ll be in a much better place as a field to think about the basis of brain states in more complex animals.”

Mary Gehring

Mary Gehring, professor of biology and core member and David Baltimore Chair in Biomedical Research at the Whitehead Institute for Biomedical Research, studies how plant epigenetics modulates plant growth and development, with a long-term goal of uncovering the essential genetic and epigenetic elements of plant seed biology. Ultimately, the Gehring Lab’s work provides the scientific foundations for engineering alternative modes of seed development and improving plant resiliency at a time when worldwide agriculture is in a uniquely precarious position due to climate changes.

The Gehring Lab uses genetic, genomic, computational, synthetic, and evolutionary approaches to explore heritable traits by investigating repetitive sequences, DNA methylation, and chromatin structure. The lab primarily uses the model plant A. thaliana, a member of the mustard family and the first plant to have its genome sequenced.

“I’m pleased that HHMI has been expanding its support for plant biology, and gratified that our lab will benefit from its generous support,” Gehring says. “The appointment gives us the freedom to step back, take a fresh look at the scientific opportunities before us, and pursue the ones that most interest us. And that’s a very exciting prospect.”

Mehrad Jazayeri

Mehrdad Jazayeri, a professor of brain and cognitive sciences and an investigator at the McGovern Institute for Brain Research, studies how physiological processes in the brain give rise to the abilities of the mind. Work in the Jazayeri Lab brings together ideas from cognitive science, neuroscience, and machine learning with experimental data in humans, animals, and computer models to develop a computational understanding of how the brain creates internal representations, or models, of the external world.

Before coming to MIT in 2013, Jazayeri received his BS in electrical engineering, majoring in telecommunications, from Sharif University of Technology in Tehran, Iran. He completed his MS in physiology at the University of Toronto and his PhD in neuroscience at New York University.

With his appointment to HHMI, Jazayeri plans to explore how the brain enables rapid learning and flexible behavior — central aspects of intelligence that have been difficult to study using traditional neuroscience approaches.

“This is a recognition of my lab’s past accomplishments and the promise of the exciting research we want to embark on,” he says. “I am looking forward to engaging with this wonderful community and making new friends and colleagues while we elevate our science to the next level.”

Gene-Wei Li,

Gene-Wei Li, associate professor of biology, has been working on quantifying the amount of proteins cells produce and how protein synthesis is orchestrated within the cell since opening his lab at MIT in 2015.

Li, whose background is in physics, credits the lab’s findings to the skills and communication among his research team, allowing them to explore the unexpected questions that arise in the lab.

For example, two of his graduate student researchers found that the coordination between transcription and translation fundamentally differs between the model organisms E. coli and B. subtilis. In B. subtilis, the ribosome lags far behind RNA polymerase, a process the lab termed “runaway transcription.” The discovery revealed that this kind of uncoupling between transcription and translation is widespread across many species of bacteria, a study that contradicted the long-standing dogma of molecular biology that the machinery of protein synthesis and RNA polymerase work side-by-side in all bacteria.

The support from HHMI enables Li and his team the flexibility to pursue the basic research that leads to discoveries at their discretion.

“Having this award allows us to be bold and to do things at a scale that wasn’t possible before,” Li says. “The discovery of runaway transcription is a great example. We didn’t have a traditional grant for that.”